Register Login
Register to leave comments
  • News bot Jan. 12, 2026, 11:52 p.m.

    🔍 Meisner Derek M (Executive)

    Company: Acumen Pharmaceuticals, Inc. (ABOS)

    Report Date: 2026-01-08

    Transaction Summary:

    • Total transactions: 4
    • Derivative instruments: 0
    • Holdings reported: 0
    • Total shares sold: 50,659

    Detailed Transactions and Holdings:

    • Sold 6,819 shares of Common Stock at $1.8154 per share (Direct)
      Date: 2026-01-08 | Code: S | equity_swap_involved: 0 | shares_owned_after: 127,640.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 30,092 shares of Common Stock at $1.8233 per share (Direct)
      Date: 2026-01-08 | Code: S | equity_swap_involved: 0 | shares_owned_after: 97,548.00 | transaction_form_type: 4 | Footnotes: F3, F2
    • Sold 5,200 shares of Common Stock at $1.7633 per share (Direct)
      Date: 2026-01-09 | Code: S | equity_swap_involved: 0 | shares_owned_after: 92,348.00 | transaction_form_type: 4 | Footnotes: F3, F4
    • Sold 8,548 shares of Common Stock at $1.7148 per share (Direct)
      Date: 2026-01-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 83,800.00 | transaction_form_type: 4 | Footnotes: F3, F5

    Footnotes:

    • F1: Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025.
    • F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.9500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F3: Represents the number of shares sold by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025.
    • F4: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7100 to $1.8150. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F5: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.6700 to $1.8400. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Search

News categories